Shares

16 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2021

Oct 26, 2021

SELL
$282.99 - $369.05 $191,584 - $249,846
-677 Closed
0 $0
Q2 2021

Jul 26, 2021

BUY
$259.0 - $414.71 $175,343 - $280,758
677 New
677 $234,000
Q4 2020

Feb 03, 2021

SELL
$236.26 - $355.63 $2.97 Million - $4.47 Million
-12,563 Closed
0 $0
Q3 2020

Oct 26, 2020

BUY
$264.77 - $305.71 $22,505 - $25,985
85 Added 0.68%
12,563 $3.56 Million
Q2 2020

Jul 27, 2020

SELL
$258.66 - $342.55 $3.06 Million - $4.06 Million
-11,847 Reduced 48.7%
12,478 $3.34 Million
Q1 2020

Apr 27, 2020

SELL
$268.85 - $341.04 $187,119 - $237,363
-696 Reduced 2.78%
24,325 $7.7 Million
Q4 2019

Jan 27, 2020

BUY
$220.06 - $304.07 $5.51 Million - $7.61 Million
25,021 New
25,021 $7.42 Million
Q3 2019

Oct 25, 2019

SELL
$217.44 - $243.88 $959,562 - $1.08 Million
-4,413 Closed
0 $0
Q2 2019

Jul 30, 2019

SELL
$219.29 - $241.72 $3.81 Million - $4.2 Million
-17,371 Reduced 79.74%
4,413 $1.03 Million
Q1 2019

Apr 25, 2019

BUY
$216.71 - $338.96 $1.06 Million - $1.66 Million
4,886 Added 28.91%
21,784 $5.15 Million
Q4 2018

Jan 25, 2019

SELL
$278.5 - $352.75 $186,316 - $235,989
-669 Reduced 3.81%
16,898 $5.09 Million
Q3 2018

Oct 30, 2018

SELL
$293.51 - $383.83 $71,029 - $92,886
-242 Reduced 1.36%
17,567 $6.21 Million
Q2 2018

Jul 25, 2018

SELL
$257.52 - $306.91 $187,989 - $224,044
-730 Reduced 3.94%
17,809 $5.17 Million
Q1 2018

Apr 26, 2018

SELL
$260.13 - $367.91 $35,377 - $50,035
-136 Reduced 0.73%
18,539 $5.08 Million
Q4 2017

Jan 29, 2018

SELL
$307.64 - $344.58 $87,062 - $97,516
-283 Reduced 1.49%
18,675 $5.95 Million
Q3 2017

Oct 16, 2017

BUY
$281.15 - $329.69 $5.33 Million - $6.25 Million
18,958
18,958 $5.94 Million

Others Institutions Holding BIIB

About BIOGEN INC.


  • Ticker BIIB
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Drug Manufacturers—General
  • Shares Outstandng 144,000,992
  • Market Cap $20.2B
  • Description
  • Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases. The company offers TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; and FUMADERM to treat plaque psoriasis. It also provides BENEPALI, an eta...
More about BIIB
Track This Portfolio

Track Meritage Portfolio Management Portfolio

Follow Meritage Portfolio Management and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Meritage Portfolio Management, based on Form 13F filings with the SEC.

News

Stay updated on Meritage Portfolio Management with notifications on news.